HER2-positive breast cancer has a higher risk of recurrence even after standard chemotherapy and trastuzumab treatment. Neoadjuvant therapy prior to surgery provides benefits like potential downstaging and increased operability. Additionally, achieving pathological complete response (pCR) with neoadjuvant treatment correlates with improved survival. Optimal evaluation and selection of appropriate candidates for neoadjuvant therapy is thus critical. This review examines systemic neoadjuvant and adjuvant treatment strategies for HER2+ breast cancer to help guide clinical decision-making surrounding therapy selection. Key factors are assessing nodal involvement and recurrence risk to determine best approach, considering postsurgical outcomes with each strategy, and utilizing adjuvant T-DM1 if pCR is not achieved with neoadjuvant therapy in the case of residual disease.
羅氏大藥廠股份有限公司
羅氏大藥廠專注於重大未滿足醫療需求及具專業之領域，包含癌症、免疫、感染性疾病、眼科及中樞神經系統五大領域。自創立以來，已陸續推出多種深受醫藥界和患者推崇的優良產品，例如：神經安定劑、抗巴金森氏症藥物、抗生素、干擾素、紅血球生成素、抗病毒藥物、器官移植抗排斥劑、抗癌製劑、流行性感冒藥物、B型及C 型肝炎製劑、類風濕性關節炎製劑及免疫療法。